FMP
Jan 14, 2026
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) is a biotechnology company focused on developing novel therapeutics. The company is gaining attention due to a recent price target adjustment by Piper Sandler, which set a new target of $37, up from $27.50. This suggests a potential increase of 54.23% from its current price of $23.99, as highlighted by TheFly.
The stock has received a "Moderate Buy" consensus from eight brokerages. Among these, six analysts recommend buying, one suggests a strong buy, and one advises selling. The average one-year target price is $30.20. Notably, Wells Fargo increased its price target from $22.00 to $30.00, giving an "overweight" rating.
GLUE's stock price has shown some volatility, with a recent increase of 1.14% or $0.27, reaching a high of $24.12 and a low of $23.25 today. Over the past year, the stock has fluctuated between $3.50 and $25.77. The company's market capitalization is approximately $1.56 billion, with a trading volume of 1,385,520 shares on the NASDAQ.
Recent analyst activity includes Weiss Ratings reiterating a "sell" rating, while Cowen reaffirmed a "buy" rating. Jefferies Financial Group also maintained a "buy" rating. These varied opinions reflect differing views on the company's future performance, contributing to the stock's current market dynamics.

In times of rising geopolitical tension or outright conflict, defense stocks often outperform the broader market as gove...

As Circle Internet (NYSE:CRCL) gains attention following its recent public listing, investors are increasingly scrutiniz...

LVMH Moët Hennessy Louis Vuitton (OTC:LVMUY) is a global leader in luxury goods, offering high-quality products across f...